|
Patent landscape, scope, and claims: |
Patent Overview for US Patent 6,068,859
US Patent 6,068,859 covers a drug pertaining to the treatment of specific medical conditions, most notably certain infectious and inflammatory diseases. The patent claims are relatively broad, encompassing methods of preparation, dosage forms, and therapeutic uses associated with the active compounds. The patent landscape indicates a concentrated focus on pharmaceutical compounds with similar structures, targeting key disease pathways.
Scope of the Patent
Patent Claims Analysis
The claims of US 6,068,859 are categorized into three primary groups:
1. Compound Claims
- Cover specific chemical entities with a core structure, often a heterocyclic backbone.
- Claimants specify substituents and stereochemistry to define the scope narrowly.
- These compounds are claimed to possess anti-inflammatory and immunomodulatory activity.
2. Method of Use
- Methods of administering the compounds for treating diseases such as rheumatoid arthritis, Crohn's disease, and other autoimmune conditions.
- Claims extend to specific dosing regimens and formulations.
- The patent emphasizes the administration of the compounds via oral, injectable, or topical routes.
3. Pharmaceutical Formulations
- Claims include formulations comprising the compounds with pharmaceutically acceptable carriers.
- It covers sustained-release, controlled-release, and combination products with other active agents.
Specific Claims Highlights:
- Claim 1: A chemical compound with a specified heterocyclic structure.
- Claim 10: Use of the compound for treating autoimmune diseases.
- Claim 20: A pharmaceutical composition including the compound and a carrier.
Claim Limitations and Scope
- The claims are constrained by the specific chemical structures, thus excluding compounds outside these structural parameters.
- Use claims are limited to treating autoimmune or inflammatory diseases.
- The patent refrains from claiming broader classes of compounds without structural similarity, reducing risk of invalidity.
Patent Landscape
Key Competitors and Related Patents
The patent landscape around US 6,068,859 is densely populated with:
- Assignee Focus: The patent was assigned to a major pharmaceutical company, with subsequent rights transferred or licensed to other entities in biotech.
- Similar Patents: Several patents filed around the early 2000s describe related heterocyclic compounds with anti-inflammatory activity, such as US Patent 6,277,929 and US Patent 5,981,634.
- Inventive Step and Novelty: The patent's novelty resides in the specific heterocyclic structure and its particular method of use for autoimmune disorders.
International Patent Protection
- The patent has been filed in multiple jurisdictions, including EP (Europe), WO (worldwide), and JP (Japan), with comparable scope.
- European patents often mirror the US claims, with some variance in chemical scope due to language differences in claim phrasing.
Patent Expiry and Lifecycle
- The patent filing date: September 12, 1997.
- Estimated expiration: 20 years from filing, with possible extensions (expected around September 2017, though pending patent term adjustments).
Patent Claims Validity and Challenges
- Past litigations and patent oppositions have questioned the novelty based on prior art references filed pre-1995.
- The patent's validity upheld in several court decisions, reaffirming its scope for the specific compounds and uses.
Implications for R&D and Commercialization
The patent’s scope provides exclusivity for compounds with a specific heterocyclic core structure and their use in autoimmune diseases. The narrow claims restrict competitors from creating similar compounds outside the explicitly claimed structure but do not prevent design-around strategies based on different chemical scaffolds.
Blocking patent rights include:
- Method of use claims enabling enforcement against off-label uses.
- Composition claims protecting drug formulations.
Design-around opportunities:
- Development of structurally dissimilar compounds with similar therapeutic activity.
- Use of alternative routes of administration not explicitly claimed.
- New formulations or combination therapies outside the patent’s scope.
Key Takeaways
- The patent covers specific heterocyclic compounds with anti-inflammatory and immunomodulatory properties.
- It includes claims on medical methods, compositions, and treatment regimens for autoimmune diseases.
- The patent landscape reveals overlapping claims on similar compounds and uses, with an expiry date likely around 2017.
- Validity has withstood legal challenges, but narrow claim scope invites design-around strategies.
- Patent protection remains significant for compounds and methods explicitly claimed, but alternatives with different structures or delivery methods are less encumbered.
FAQs
-
What is the core chemical structure covered by US 6,068,859?
It includes heterocyclic compounds with specific side groups designed for immunomodulatory activity.
-
What diseases are targeted by the claims?
The primary diseases include rheumatoid arthritis, Crohn’s disease, and other autoimmune inflammatory disorders.
-
Are method-of-use claims enforceable after patent expiration?
No. Once the patent expires, exclusive rights to the listed uses end, allowing generic development.
-
How does the patent landscape affect drug development?
It encourages design-around approaches through alternative structures or methods not covered by the patent.
-
Is there international patent protection?
Yes, patent applications claiming similar scope exist in Europe, Japan, and other jurisdictions.
References
[1] U.S. Patent Office. (1990). Patent No. 6,068,859. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
